The patient population RxUtility is built for is easy to picture: the person standing at a pharmacy counter who hears the price, swallows hard, and walks out without the bottle. According to a December 2025 report the company itself published, Americans abandon roughly 98 million prescriptions annually because of cost [Business Wire, Dec 2025]. The disease states span the entire chronic-care spectrum, hypertension, diabetes, asthma, mental health, where a missed fill is not a minor inconvenience but a clinical event that drives ER visits, hospitalizations, and avoidable progression.
Nashville-based RxUtility, founded by health IT veteran Miriam Paramore, is trying to make that walk-away moment less common by giving every actor in the prescription chain the same real-time view of what a drug will actually cost the patient. The company sells an API that aggregates manufacturer copay coupons and surfaces real-time cash discount card pricing at every pharmacy [RxUtility]. The pitch to providers, pharmacists, employers, payers, and digital health partners is straightforward: stop guessing at the counter, and stop sending patients home to comparison shop on coupon sites.
The standard of care today
Medication affordability in the United States is currently held together by a patchwork. A prescriber writes a script with little visibility into what the patient will pay at their specific pharmacy under their specific plan. The pharmacist runs the claim, quotes a price, and, if the patient balks, may suggest a GoodRx-style discount card, hunt for a manufacturer coupon PDF, or call the prescriber to switch to a cheaper alternative. Manufacturer copay assistance programs exist for hundreds of branded drugs but are fragmented across brand websites, hub services, and paper cards. Real-time prescription benefit tools inside EHRs have improved over the last five years, particularly for Medicare Part D, but cash and coupon pricing often sits outside that workflow. The result is the abandonment number RxUtility cites, and a clinical reality where adherence drops sharply the moment out-of-pocket cost crosses a patient's personal threshold.
The bet
RxUtility's wedge is the data layer underneath that mess. The company describes its product as an aggregated database of all manufacturer copay coupons paired with real-time cash discount card pricing at every pharmacy, delivered via API so partners can embed savings directly into their own workflows [RxUtility]. That is a different posture from a consumer-facing discount brand. RxUtility is not asking patients to download an app. It is asking the systems patients already touch, the e-prescribing tool, the pharmacy management system, the employer benefits portal, the digital health app, to surface a better price automatically.
In February 2026, the company announced a partnership with Buzz Health to boost medication price transparency for consumers, a deal framed as connecting providers, pharmacists, employers, payers, and digital health partners with real-time access to copay assistance and pricing [Business Wire, Feb 2026]. It is an early but meaningful validation that the API-first approach has buyers on the other end.
Opportunity
The tailwinds here are unusually aligned. The Inflation Reduction Act's drug pricing provisions, ongoing CMS pressure on PBM transparency, and employer frustration with specialty drug spend have all pushed price transparency from a nice-to-have into a procurement requirement. Direct primary care practices, which operate largely outside insurance, are actively looking for cash-pay tooling. Paramore has been spotted at the Hint Summit, the main DPC industry gathering, describing herself as an all-cash patient learning how RxUtility can help that community [LinkedIn]. That is a small but telling signal about where the early demand is coming from.
The addressable surface is large. If even a single-digit percentage of the 98 million abandoned prescriptions per year are recoverable through better point-of-sale price visibility, the clinical and economic impact compounds quickly across chronic disease cohorts where adherence is the single biggest determinant of outcomes [Business Wire, Dec 2025].
Abandoned US prescriptions per year (millions) | 98 | M
The team and traction
Paramore is the CEO and founder, and her resume is the clearest asset on the cap table [Business Wire, Dec 2025]. She was appointed President of OptimizeRx in 2017, where she focused specifically on medication affordability, compliance, and real-time coupon distribution at the point of care [GlobeNewswire, Jul 2017]. Before that she held senior roles including COO and CTO of digital health marketplace Lucro, EVP at retail pharmacy IT vendor PDX, and EVP of Strategy and Product at Emdeon, the company that became Change Healthcare [Fierce Healthcare]. That is more than 30 years inside the exact plumbing RxUtility now needs to integrate with [Fierce Healthcare]. The Buzz Health partnership in February 2026 is the most recent external proof point [Business Wire, Feb 2026].
The honest counterfactual
Bears will say that the real-time prescription pricing category already has well-funded incumbents. GoodRx owns consumer mindshare on cash discount cards. OptimizeRx, Paramore's former employer, sits inside EHR workflows for branded copay messaging. Surescripts and the major EHR vendors have invested heavily in real-time benefit check infrastructure on the insured side. Any new API entrant has to convince integration partners that a single aggregated source is worth swapping in for tooling they already license. Bulls will answer that none of those incumbents combine cash discount pricing, manufacturer coupons, and pharmacy-level real-time data in one developer-facing API, and that the buyer set RxUtility is courting (DPC clinics, employer benefits platforms, digital health apps) is precisely the segment underserved by tools designed for traditional payer workflows. Paramore's time inside OptimizeRx and Emdeon means she knows exactly where the gaps are.
What to watch
The next 12 months will turn on three things. First, additional named integration partners in the mold of Buzz Health, particularly any pharmacy management system or EHR-adjacent vendor, would signal the API is being adopted as infrastructure rather than as a one-off data feed. Second, watch for any disclosed institutional funding round; the category is capital-intensive once you start signing enterprise integrations and indemnifying partners on pricing accuracy. Third, watch whether RxUtility publishes outcomes data, ideally a peer-reviewed or third-party-audited study showing measurable lift in fill rates for a defined patient cohort. Until that exists, the 98 million number remains the problem statement, not the proof of solution. If that evidence arrives, the conversation about RxUtility shifts from interesting plumbing to clinical tool, and the buyer list gets considerably longer.